Factors influencing first remission and survival in 145 dogs with lymphoma: a retrospective study

Records of 145 dogs diagnosed with lymphoma were reviewed to evaluate for factors influencing duration of remission and survival. Dogs with histories of certain chronic inflammatory diseases were 3.23 times more likely to relapse (relative risk, 3.23) than the overall population. Dogs with World Health Organization (WHO) stage IV lymphoma or those treated with a protocol containing cyclophosphamide, doxorubicin, vincristine, prednisone, and sulfatrimethoprim (CHOP) had lower relative risks of relapse (0.32 and 0.085, respectively). Progressive disease after induction, gastrointestinal toxicity from induction, and clinical signs (i.e., substage b lymphoma) were associated with higher relative risks of death (3.5, 2.64, and 2.02, respectively).

This article has been cited by other articles:

				J. D. Frank, S. B. Reimer, P. H. Kass, and M. Kiupel Clinical Outcomes of 30 Cases (1997 2004) of Canine Gastrointestinal Lymphoma J. Am. Anim. Hosp. Assoc., November 1, 2007; 43(6): 313 - 321. [Abstract] [Full Text] [PDF]

				C. I. Kaiser, J. L. Fidel, M. Roos, and B. Kaser-Hotz Reevaluation of the University of Wisconsin 2-Year Protocol for Treating Canine Lymphosarcoma J. Am. Anim. Hosp. Assoc., March 1, 2007; 43(2): 85 - 92. [Abstract] [Full Text] [PDF]

				C. B. Greenberg, P. A. Boria, A. Borgatti-Jeffreys, R. E. Raskin, and M. D. Lucroy Phase II Clinical Trial of Combination Chemotherapy With Dexamethasone for Lymphoma in Dogs J. Am. Anim. Hosp. Assoc., January 1, 2007; 43(1): 27 - 32. [Abstract] [Full Text] [PDF]